Month: May 2024

OTTAWA, May 03, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Friday, May 10, 2024 at 10:30 a.m. ET to discuss its financial results for the three month period ended March 31, 2024. The call will be hosted by Daniel S. Goldberg, President and Chief Executive Officer, and Andrew Browne, Chief Financial Officer, of Telesat. Prior to the commencement of the call, Telesat will post a news release containing its financial results on its website (www.telesat.com) under the tab “Investors” and the heading “Investor News”. Dial-in Instructions: The toll-free dial-in number for the teleconference is +1 800 806 5484. Callers outside of North America should dial +1 416 340 2217. The access code is 6484355 followed by the number...

LOS ANGELES, May 03, 2024 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products, today announced its entry into a distribution agreement (“Agreement”) with Kinsey’s Inc. to distribute AXIL hearing protection and enhancement products including AXIL GS Extreme 2.0®, XCOR®, XCOR Digital®, and the Trackr™ series hearing solutions. “Our partnership with Kinsey’s is an important step in providing retailers greater access to AXIL products. Kinsey’s has long been regarded a top tier distributor with the highest quality of service and business values. We are confident our partnership with Kinsey’s will provide AXIL dealers and retailers outstanding service and support,” said Jeff Toghraie,...

— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — — Multiple presentations of preclinical data demonstrate the potential of the PREDATORTM platform, including in immunology-based diseases — — Company announces cash runway extension through at least the first quarter of 2026 — WATERTOWN, Mass., May 03, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other...

SHANGHAI, China, May 03, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today announced the launch of multiple intelligent driving and safety features for its Skyland Pro computing platform, which significantly enhance the intelligent driving experience. The new features were previewed during ECARX’s second Tech Day, which was held in Hangzhou on March 20, 2024, and were released for the first time in the recent version 1.4.0 update for the “Lynk Co-Pilot Navi” smart navigation assistance system on Lynk & Co. 08 EM-P. Leveraging the power of Skyland Pro’s dual system-on-a-chip architecture, the update included a number of L2+ assisted driving and parking features, including highway Navigate-on-Autopilot (NOA), Automatic Parking Assist (APA), and...

– Trial did not meet primary endpoint – IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 weeks in a total of 325 analyzed patients randomized across three arms showed a reduction of 8.5 days in the 150 U arm and 7.7 days in the 195 U arm, compared with a reduction of 8.4 days in the placebo arm. These differences...

FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), and Steven Lin, M.D. (MD Anderson Cancer Center), who will discuss below topics:Plinabulin history and development strategy for cancer Plinabulin’s...

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) is pleased to announce that its common shares have commenced trading on the OCTQB under the symbol PAUIF. The listing complements PUR’s existing DTC Eligibility. Colin Healey, CEO of PUR, commented, “As a U.S. focused uranium exploration and development Company, having our shares trade on the OTCQB is an important step in unlocking value for our existing shareholders in the U.S. Additionally, with this now completed, we anticipate leveraging the OTC platform to expand our visibility to a broader network of investors, which aligns seamlessly with current uranium market dynamics, particularly within the U.S.” The OTCQB is a U.S. trading platform operated by the OTC Markets Group and...

MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 million, adjusted EBITDA(a) of $60.9 million, and free cash flow(a) of $26.8 million. Ted Harris, Chairman, President and CEO of Balchem said, “The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio.” First Quarter 2024 Financial Highlights:Net sales were a record $239.7 million, an increase of 3.1% compared to the prior year quarter. Adjusted EBITDA was a record $60.9 million,...

LATHAM, N.Y., May 03, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announced the signing of a memorandum of understanding (MOU) with Allied Green Ammonia (AGA), an Australian Company focused on green ammonia production, to supply up to 3 gigawatts (GW) of Plug electrolyzer capacity for AGA’s upcoming hydrogen to ammonia facility proposed for the Northern Territory of Australia. Following the MOU, Plug and AGA plan to enter an agreement, as outlined in the MOU, to initiate a Basic Engineering and Design Package (BEDP) for the 3GW capacity project. The BEDP is expected to advance mid-May of this year, with final investment decision (FID) planned for Q4 2025 and the progressive delivery of the 3GW electrolyzer supply slated to begin in Q1,...

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the company and to protect the interests of the company and its stockholders by reducing the likelihood that any person or group gains control of Galera...